Drug GMP Report

June 2008

OGD: Generics Must Meet New Residual Solvent Standard

When the new U.S. Pharmacopeia (USP) standard for controlling residual solvents in pharmaceuticals takes effect July 1, the FDA will require all generic drugs to comply with it, not just those with USP monographs, according to the Office of Generic Drugs (OGD).

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

FDA Delivers Final Blow to Generic Drugmakers Eyeing OxyContin Copycats FDA Questions Reckitt’s Motives in Petition Denial, OKs Suboxone ANDAs FDA Questions Reckitt Benckiser’s Motives in Petition Denial, OKs Two Suboxone Generics FDA: More Work May Be Needed to Discourage Anticompetitive Petitions

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.